Javascript must be enabled to continue!
The effect of age on COVID-19 patient's outcome
View through CrossRef
Background:
The first case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified in Wuhan, China, in late 2019. In India, the first case was reported on 30.01.2020, and first COVID-19 death occurred on 10.03.2020. The case fatality rate (CFR) was 3.4% estimate by the World Health Organization (WHO) as of 03.03.2020. All age groups had significantly higher mortality compared with the immediately younger age group. The largest increase in mortality risk was observed in patients aged 60 to 69 years compared with those aged 50 to 59 years.
Objective:
The aim of this study is to determine the effect of age on COVID-19 patient's outcome.
Methods:
All the secondary data were collected either from the Indian institute statistics, Bangalore website, or COVID-19 india website, or GitHub website, or Indian government websites. The effect of age on COVID-19 patient's outcome was determined.
Results:
Age at first quartile was 50 years in the deceased group, whereas in recovered, it was 25 years. The median age in the deceased group and recovered group were 59 and 34 years, respectively. Significant difference was observed in age between the deceased and recovered group. Age was showing a medium effect size (0.574) in the outcome of the COVID-19. The cut-off value of age for estimating risk of death was established by using Receiver Operating Characteristic (ROC) analysis. The cut-off value was 48 years. The sensitivity was 77.5% and the specificity was 78.8%. More than 48 years age group had a 13 times higher risk than the less than 48 years age group. Area under the curve was 0.855 (95% CI: 0.846–0.864).
Conclusions:
This study suggests that the strong association between the age and outcome of COVID-19 patients. We can predict the outcome of COVID-19 patient based on their age. The outcome of COVID-19 patient prediction may give better results with associated comorbid conditions. The cut-off value of age for outcome was 48 years.
Ovid Technologies (Wolters Kluwer Health)
Title: The effect of age on COVID-19 patient's outcome
Description:
Background:
The first case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified in Wuhan, China, in late 2019.
In India, the first case was reported on 30.
01.
2020, and first COVID-19 death occurred on 10.
03.
2020.
The case fatality rate (CFR) was 3.
4% estimate by the World Health Organization (WHO) as of 03.
03.
2020.
All age groups had significantly higher mortality compared with the immediately younger age group.
The largest increase in mortality risk was observed in patients aged 60 to 69 years compared with those aged 50 to 59 years.
Objective:
The aim of this study is to determine the effect of age on COVID-19 patient's outcome.
Methods:
All the secondary data were collected either from the Indian institute statistics, Bangalore website, or COVID-19 india website, or GitHub website, or Indian government websites.
The effect of age on COVID-19 patient's outcome was determined.
Results:
Age at first quartile was 50 years in the deceased group, whereas in recovered, it was 25 years.
The median age in the deceased group and recovered group were 59 and 34 years, respectively.
Significant difference was observed in age between the deceased and recovered group.
Age was showing a medium effect size (0.
574) in the outcome of the COVID-19.
The cut-off value of age for estimating risk of death was established by using Receiver Operating Characteristic (ROC) analysis.
The cut-off value was 48 years.
The sensitivity was 77.
5% and the specificity was 78.
8%.
More than 48 years age group had a 13 times higher risk than the less than 48 years age group.
Area under the curve was 0.
855 (95% CI: 0.
846–0.
864).
Conclusions:
This study suggests that the strong association between the age and outcome of COVID-19 patients.
We can predict the outcome of COVID-19 patient based on their age.
The outcome of COVID-19 patient prediction may give better results with associated comorbid conditions.
The cut-off value of age for outcome was 48 years.
Related Results
Autonomy on Trial
Autonomy on Trial
Photo by CHUTTERSNAP on Unsplash
Abstract
This paper critically examines how US bioethics and health law conceptualize patient autonomy, contrasting the rights-based, individualist...
Burden of the Beast
Burden of the Beast
Introduction
Throughout the COVID-19 pandemic, and its fluctuating waves of infections and the emergence of new variants, Indigenous populations in Australia and worldwide have re...
The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
Abstract
Introduction
Human immunodeficiency virus (HIV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) surface glycoproteins, including shared epitope motifs, sho...
PERSEPSI IBU HAMIL TENTANG VAKSIN COVID-19 TERHADAP PELAKSANAAN VAKSINASI COVID-19
PERSEPSI IBU HAMIL TENTANG VAKSIN COVID-19 TERHADAP PELAKSANAAN VAKSINASI COVID-19
Latar Belakang: kasus positif Covid-19 di Kabupaten Sukoharjo tahun 2021 mencapai 12.350 dan terus mengalami penambahan jumlah. Dari jumlah tersebut terdapat 168 kasus positif Covi...
The Impact of the Covid-19 Pandemic and Macroeconomics on the Sharia Stock Indexes in Indonesia
The Impact of the Covid-19 Pandemic and Macroeconomics on the Sharia Stock Indexes in Indonesia
ABSTRACT
The Covid-19 pandemic has changed economic conditions in various countries, including Indonesia. One of the sectors affected is the capital market sector which can also de...
Long COVID Treatment No Silver Bullets, Only a Few Bronze BBs
Long COVID Treatment No Silver Bullets, Only a Few Bronze BBs
Long COVID is the consequence of having had COVID. Long COVID has many other names including Long-haul COVID, Post-COVID conditions (PCC), Post-COVID-19 syndrome, Post-acute seque...
Long COVID Treatment No Silver Bullets, Only a Few Bronze BBs
Long COVID Treatment No Silver Bullets, Only a Few Bronze BBs
Long COVID is the consequence of having had COVID. Long COVID has many other names including Long-haul COVID, Post-COVID conditions (PCC), Post-COVID-19 syndrome, Post-acute seque...

